Elevated circulating t (14; 18) translocation levels prior to diagnosis of follicular lymphoma
KL Bretherick, R Bu, RD Gascoyne… - Blood, The Journal …, 2010 - ashpublications.org
Blood, The Journal of the American Society of Hematology, 2010•ashpublications.org
2. Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable
molecular residual disease and molecular responses with pegylated form of interferon
alpha2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic
phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18
months of part 1 of the Spirit phase III randomized trial of the French CML Group (FI
LMC)[abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114 (11): Abstract 340.
molecular residual disease and molecular responses with pegylated form of interferon
alpha2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic
phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18
months of part 1 of the Spirit phase III randomized trial of the French CML Group (FI
LMC)[abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114 (11): Abstract 340.
2. Guilhot F, Preudhomme C, Guilhot J, et al. Significant higher rates of undetectable molecular residual disease and molecular responses with pegylated form of interferon alpha2a in combination with imatinib (IM) for the treatment of newly diagnosed chronic phase (CP) chronic myeloid leukaemia (CML) patients (pts): confirmatory results at 18 months of part 1 of the Spirit phase III randomized trial of the French CML Group (FI LMC)[abstract]. Blood (ASH Annual Meeting Abstracts). 2009; 114 (11): Abstract 340.
ashpublications.org